Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1641 1642 1644 1671 1681
This examiner grants 100% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18053904 | STABLE FORMULATIONS COMPRISING A BISPECIFIC BCMA/CD3 ANTIBODY | Non-Final OA | JANSSEN BIOTECH, INC. |
| 18263008 | ENHANCING METABOLIC FITNESS OF T CELLS TO TREAT CANCER | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18365950 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR GPRC5D AND BCMA | Non-Final OA | Juno Therapeutics, Inc. |
| 18261638 | USE OF IMMUNE CONTENT SCORES DIAGNOSTICALLY TO PREDICT RESPONSIVENESS OF PROSTATE CANCER PATIENTS TO IMMUNOTHERAPY | Non-Final OA | Northwestern University |
| 18285205 | CITRULLINATED PROTEINS AS BIOMARKERS AND THERAPY TARGETS FOR CANCER | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18459866 | METHOD FOR IMPROVING WOUND HEALING | Non-Final OA | NATIONAL YANG MING CHIAO TUNG UNIVERSITY |
| 18490500 | ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS | Non-Final OA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy